Veracyte Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Veracyte Inc in the second quarter 2026?
Veracyte Inc achieved a return on average equity (ROE) of 8.64 % in its second quarter 2026 a new company high.

While the company's net income was fading, Veracyte Inc was able to improve its ROE compared to the first quarter 2026.

Within the Medical Laboratories industry 9 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1657 to 1766.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	13.71 %	12.51 %	11.36 %	6.94 %	-
Y / Y Net Income Change	-	307.36 %	704.79 %	26.28 %	-
Net Income (TTM) in Millions	114	88	66	30	26
Return On Equity (TTM)	8.64 %	6.86 %	5.33 %	2.5 %	2.21 %
VCYT's Total Ranking	# 1766	# 1657	# 1728	# 1973	# 1323
Equity (TTM) in Millions	1,388	1,344	1,310	1,258	1,221
Seq. Equity Change	3.27 %	2.66 %	4.13 %	3 %	2.19 %
Seq. Net Income Change	-11.21 %	-30.24 %	115.02 %	-	-

Back to VCYT Management Effectiveness >> VCYT's 5 Years Annual ROE >> Compare VCYT ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 10
Sector	# 154
Overall	# 1766

Return On Equity Statistics
High	Average	Low
8.64 %	-30.72 %	-135.8 %
(Jun 30 2026)		(Jun 30 2014)

VCYT Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	1,310	1,176	1,044	1,075	1,097
Y / Y Equity Change	11.36 %	12.63 %	-2.89 %	-1.94 %	160.31 %
Net Income in Millions	66	24	-74	-37	-76
Y / Y Net Income Change	174.89 %	-	-	-	-
Return On Equity	5.07 %	2.05 %	-7.13 %	-3.4 %	-6.89 %

Back to VCYT Management Effectiveness >> VCYT's 5 Years Annual ROE >> Compare VCYT ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 5.07 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
VCYT's' Return on Equity at Yahoo Finance
VCYT's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for VCYT's Competitors
Subscribers only: Roe for Veracyte Inc 's Suppliers
Subscribers only: Return On Equity for VCYT's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Electromed Inc	23.65 %
Iradimed Corporation	23.45 %
Vertex Pharmaceuticals Inc	23.31 %
Lantheus Holdings Inc	23.27 %
Msa Safety Inc	23.15 %
Prestige Consumer Healthcare Inc	21.77 %
Jazz Pharmaceuticals Plc	21.37 %
Neurocrine Biosciences Inc	21.13 %
Universal Health Services Inc	20.89 %
Puma Biotechnology Inc	20.85 %
Entera Bio Ltd	20.82 %
United Therapeutics Corporation	20.18 %
Ligand Pharmaceuticals Incorporated	20.06 %
Harmony Biosciences Holdings inc	20.06 %
Pediatrix Medical Group Inc	19.89 %
Theravance Biopharma inc	19.40 %
Krystal Biotech Inc	19.34 %
Ani Pharmaceuticals Inc	19.33 %
Brightspring Health Services Inc	18.93 %
Sbc Medical Group Holdings Incorporated	18.69 %
West Pharmaceutical Services Inc	18.51 %
Intuitive Surgical Inc	17.82 %
Standard Biotools Inc	17.64 %
Inspire Medical Systems inc	17.62 %
Medinotec Inc	17.47 %
Lemaitre Vascular Inc	16.93 %
Ufp Technologies Inc	16.72 %
Ensign Group Inc	16.53 %
Stryker Corp	16.36 %
Nephros Inc	16.20 %

Date modified: 2026-09-02T19:45:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.